Objectives: To examine ethnoracial disparities in antidementia medication use, accounting for implementation of Part D, and to evaluate the role of prescription drug coverage as a cause of antidementia medication disparities.
Design: Rotating panel of Medicare beneficiaries who participated in the Medicare Current Beneficiary Survey from 2003 to 2013.
Setting: Nationally representative sample of Medicare fee-for-service (FFS) beneficiaries with dementia.
Participants: Community-dwelling FFS Medicare beneficiaries with dementia (N=4,304).
Measurements: Antidementia medication use, defined as at least one prescription fill in a given year.
Results: Unadjusted antidementia medication use was 10-percentage points lower for ethnoracial minority beneficiaries before Part D was implemented in 2006 (p=.01). This difference was attenuated after adjusting for demographic and socioeconomic factors (6-percentage points; p=.10). Part D was associated with a 6-percentage point increase in use (p<.01). The increase in use associated with Part D was higher although not statistically significantly so in ethnoracial minority beneficiaries (8-percentage points, p=.08). Analyses of each ethnoracial group found a significant effect of Part D only in Hispanic/Latino beneficiaries (18-percentage points; p<.01, adjusted).
Conclusion: Antidementia medication disparities were reduced with expanded prescription drug coverage through Medicare Part D. Increases in antidementia medication use for minority beneficiaries started after Part D was implemented, with the largest increases in use observed in Hispanic/Latino beneficiaries.
Keywords: Medicare Part D; antidementia medication; cholinesterase inhibitor; dementia; disparities.
© 2018, Copyright the Authors Journal compilation © 2018, The American Geriatrics Society.